DiaMedica schedules Oct. 23 webinar to present interim Phase 2 early-onset fetal growth restriction data for DM199

• DiaMedica Therapeutics set an Oct. 23, 2026 virtual KOL webinar on DM199 in early-onset fetal growth restriction.
• Early interim topline findings from the first Phase 2 cohort were already generated, with safety and initial trial observations to be presented.
• Enrollment finished for the first cohort; dosing has started in the second cohort, marking the first use of DM199 in early-onset FGR.
• Management framed the initial readout as supporting further evaluation of DM199 as a potential treatment option in FGR.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300830BIZWIRE_USPR_____20260930_BW867672) on September 30, 2026, and is solely responsible for the information contained therein.